AstraZeneca Gilead Merger Intriguing But Unlikely

Bloomberg Rumor Causes A Stir

The possible creation of a pharma giant worth around $230bn of two firms who are leading the industry’s efforts to combat COVID-19 has caught the imagination but the likelihood of a match is limited.

Proposal_Rings
Observers hoping for a mega-merger may have to wait a while longer • Source: Shutterstock

Observers of the pharmaceutical industry got a surprise wake-up call on Sunday (7 June) with a report that AstraZeneca PLC had approached Gilead Sciences Inc. about a potential merger and spent the rest of the day weighing up the pros and cons of a deal that could create a healthcare giant worth over $230bn.

Bloomberg reported that AstraZeneca had made a preliminary approach to Gilead about a potential merger last month citing unnamed sources...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.